4:27 AM ET March 7, 2000
ISELIN, N.J. (Dow Jones)--Pharmos Corp. (PARS) completed the third cohort of its Phase II clinical trial for its dexanabinol traumatic brain injury treatment.
In a press release Tuesday, the drug company said the studies established the safety of dexanabinol and demonstrated the drug's efficacy in preventing the elevation of intercranial pressure after head trauma.
Pharmos plans to begin an international pivotal trial of the drug on several hundred patients later this year.
The company said Monday that dexanabinol may also supress the pathological features of multiple sclerosis.
Pharmos shares closed in Nasdaq SmallCap trading Monday up 3 1/4, or
at 13 1/2.
-Roy R. Reynolds; Dow Jones Newswires; 201-938-5400